Morgan Stanley downgraded Allergen (NYSE: AGN) from Overweight to Equalweight.

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

Lazard Capital Upgrades Allergen (AGN) to BuyMay 2, 2013 7:11 AM Reduced Competition Adds $35 to Regeneron (REGN) DCF, Deutsche Bank Raises PT to $310May 1, 2013 12:55 PM Allergan (AGN) Strong With or Without DARPin - RBCMay 1, 2013 12:02 PM Allergan (AGN) Says DARPin to Be Delayed, Shares Sag; Regeneron (REGN) Ramps HigherMay 1, 2013 11:26 AM Regeneron (REGN) Share Spike, Volatility Halt Appears Related to Allergan NewsMay 1, 2013 11:13 AM Allergan (AGN) says Darpin data does not support Phase 3 trials.May 1, 2013 11:08 AM Allergan, Inc. (AGN) trading paused for volatilityMay 1, 2013 11:06 AM